View Author
ifn -β effect type i ifns treatment bxpc -3 cells expression cancer protein combination ifn -α activation growth activity control interferon receptor p 27 expression phosphorylation secretion increase *** concentration inhibition vitale pathway hormone stat -3 factor pancreatic signi response experiment tumor type i interferons pancreatic cancer cells cycle ifnar signi ficantly analysis mechanism patient autophagy survival troglitazone van koetsveld pm eif 4e phosphorylation cytokine kinase ppar -γ antitumor activity tecnology inc caraglia biotechnology transfection administration agent prolactin agonist metab beclin 4 ° c injection apoptosi error bars cortisol pancreatic cancer decrease binding advance incubation change method hepatitis §§§ speci level therapy endocrinol adenomas methods ”.
2 Most Recent Publications
|
The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells
(Article)
Vitale, G. Zappavigna, S. Piccoletti, R. Koetsveld, P.M. van Cavagnini, F. Budillon, A.M. Abbruzzese, A. Hofland, L.J. Caraglia, M. Marra, M. Dicitore, A. Meschini, S. Condello, M. Arancia, G. Castiglioni, S. Maroni, P. Bendinelli, P. |
2012-01-01
|
|
Potential role of type i interferons in the treatment of pituitary adenomas
(Article)
Vitale, G. Caraglia, M. Koetsveld, P.M. van Maroni, P. Marra, M. Colao, A. Lamberts, S.W.J. Cavagnini, F. Hofland, L.J. |
2009-06-01
|
